Skip to main content
. 2015 Dec 29;11(3):1005–1010. doi: 10.3892/etm.2015.2958

Figure 1.

Figure 1.

Rolipram improves functional outcome and decreases infarction size. (A) Behavioral tests showed that rolipram significantly improved functional outcome. The mNSSs in groups receiving rolipram therapies were significantly lower than those in the vehicle group (#P<0.01). In addition, the declining curve of the mNSS in the 14 days group was more evident than that in the seven and three days groups ($P<0.05). (B and C) The infarcted area, shown by triphenyltetrazolium chloride staining (white), was prominent in the vehicle group but reduced in the rolipram-treated group (# P<0.05). mNSS, modified neurological severity score; SE, standard error.